Gevorg Tamamyan: Albania’s Vision for the Future of Pediatric Oncology
Gevorg Tamamyan, Editor-in-Chief of OncoDaily, and the President of SIOP Asia and POEM Group, shared a post on LinkedIn:
“Beautiful country. Beautiful people.
Even this short trip was enough to truly feel Albania. A wonderful nation hidden between green mountains and mighty sea waves.
A warm country; one that stays warm even on a freezing day, thanks to the inner warmth and genuine smiles of its beautiful people.
So much energy. So much passion. So much life.
Though small in size, Albania generates enormous positive energy.
And they have amazing plans and powerful aspirations to make Albania a top destination for pediatric oncology.
A place where compassionate, comprehensive care walks hand in hand with scientific breakthroughs.
For every child with cancer. For every family.
There is a clear vision. A concrete plan for the coming years. And I am confident they will make it happen.
Great people. Great leaders. Great doers.
Thank you for the warm hospitality and for sharing your inspiring vision.
The best is yet to come.
P.S. And they have a great food. ”
Other posts featuring Gevorg Tamamyan on Hemostasis Today.
-
Apr 14, 2026, 17:32Denise M.: Surviving Sepsis 2026 – The Upstream Revolution
-
Apr 14, 2026, 17:23Meghanath Yenni։ What’s New in Acute Ischemic Stroke in 2026
-
Apr 14, 2026, 17:11Phil Spinella: What Dose of TXA for Children With Severe Traumatic Bleeding Should You Use?
-
Apr 14, 2026, 17:08Abdulrahman Katib: How Endovascular Stenting Is Transforming the Treatment of Severe PTS
-
Apr 14, 2026, 17:00Anna A. Avagyan: Glad to Be Part of EHA Pediatric Hematology-Oncology Course
-
Apr 14, 2026, 16:58Ney Carter Borges: NLRP3 Inhibition in Atherosclerosis – Early Clinical Signal Beyond Lipids
-
Apr 14, 2026, 16:56Saskia Middeldorp: Key Takeaways from the 2026 ACC/AHA Guideline on Acute PE
-
Apr 14, 2026, 16:54Chokri Ben Lamine: Extracorporeal Photopheresis for aGVHD cGVHD Post-SCT – 50 Pearls
-
Apr 14, 2026, 16:49Ahmed Magdi Omar: Key Takeaways From the Latest 2026 Guidelines on Antiplatelet Therapy in AIS